A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Non-small cell lung cancer is sometimes driven by a faulty gene called ALK. This is known as ALK-positive lung cancer. Doctors usually treat it with targeted tablets, but the cancer can eventually find ways to resist these drugs. This trial is looking at an experimental targeted medicine called TRI-611. The main goals are to find the safest dose with the fewest side effects, and to see if the drug can help control or shrink tumours. The study has two stages. The first stage tests different dose levels to find the safest amount to give. The second stage tests how well TRI-611 works across different groups of patients, based on the cancer treatments they have had in the past. People in the trial take the medicine regularly, keep a diary, and visit the hospital for routine health and scan checks.
At a glance
What is this study about?
Some types of non-small cell lung cancer have a specific change in their genes called an ALK rearrangement. This genetic change acts like an 'on switch', telling cancer cells to grow and spread. Standard care often involves targeted drugs that block this signal. While these drugs can work very well, the cancer can change over time and stop responding, leaving patients in need of new options.
TRI-611 is a new investigational targeted drug designed to block the ALK signal. Researchers hope it may work against lung cancer cells, including forms of the disease that have become resistant to other medicines. This trial is divided into two phases to carefully evaluate how TRI-611 behaves in the human body.
In the first part, doctors will give small, carefully monitored doses to a few patients. They will slowly increase the dose to find the best balance between safety and strength. In the second part, more patients will receive the chosen dose. This stage includes groups of people who have already tried several other ALK treatments, as well as a group who have never had targeted therapy before.
By taking part, participants help doctors learn whether TRI-611 is a safe and helpful treatment option for people living with ALK-positive lung cancer in the future.
Key takeaways
- Tests a new targeted medicine (TRI-611) for ALK-positive non-small cell lung cancer.
- Aims to find the safest dose and check how well it controls cancer growth.
- Open to adults who have had previous targeted therapies, as well as those who have had none.
- Requires frequent hospital visits in the first three months, followed by monthly check-ups.
- Participation is entirely voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is for adults aged 18 and over who have been diagnosed with ALK-positive non-small cell lung cancer that can be measured on a scan. Patients must have reasonably good general health, including satisfactory blood counts and kidney and liver function.
Because the trial has different groups, past treatment requirements vary. Some groups are looking for people who have already taken specific targeted medicines, such as lorlatinib. Another group is open to patients who have never had any ALK-targeted treatment before. Your doctor can help determine which group fits your treatment history.
You cannot take part if your cancer has certain other genetic changes that cause resistance, or if you have cancer spread to the brain or spine that is causing worsening symptoms or requires higher steroid doses. You also cannot join if you are currently receiving other cancer treatments, have had major surgery in the past four weeks, or have an allergy to the study drug.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have confirmed ALK-positive non-small cell lung cancer.
- My cancer can be measured on a scan.
- My general health and blood test results are suitable.
- I have not had major surgery in the last four weeks.
- Any cancer spread to my brain or spine is stable and not causing worsening symptoms.
What does participation involve?
If you join, you will take the study drug TRI-611 on an ongoing basis. You will also be asked to keep a simple daily diary to write down when you take your medicine. In the first three months, you will need to visit the hospital clinic about seven times for close monitoring. After that, visits will typically happen once every four weeks (one 28-day cycle).
During clinic visits, the medical team will carry out standard checks, such as blood tests, physical examinations, and periodic imaging scans (like CT or MRI scans) to see how your tumour is responding. You can continue taking the study drug for as long as it is helping to keep your cancer stable and the side effects remain manageable. The total time you spend on the study depends entirely on how well the treatment works for you.
Potential risks and benefits
Locations (20)
- UCSFVerified postcodeSan Francisco, United States· Recruiting
- University of Colorado Cancer CenterVerified postcodeAurora, United States· Recruiting
- Massachusetts General HospitalVerified postcodeBoston, United States· Recruiting
- Dana Farber Cancer CenterVerified postcodeBoston, United States· Recruiting
- Washington University Medical CenterVerified postcodeSt Louis, United States· Recruiting
- Memorial Sloan-Kettering Cancer CenterVerified postcodeNew York, United States· Recruiting
- Duke UniversityVerified postcodeDurham, United States· Recruiting
- University of Cincinnati Cancer CenterVerified postcodeCincinnati, United States· Recruiting
- Taylor Cancer Research CenterVerified postcodeMaumee, United States· Recruiting
- UPMC Hillman Cancer CenterVerified postcodePittsburgh, United States· Recruiting
- SCRI Oncology PartnersVerified postcodeNashville, United States· Recruiting
- Oncology Consultants Research (P1 Trials)Verified postcodeHouston, United States· Recruiting
Common questions
What does ALK-positive mean?
It means your lung cancer cells have an altered version of the ALK gene. This gene change produces an abnormal protein that causes the cancer to grow.
Is TRI-611 a chemotherapy drug?
No. TRI-611 is a targeted therapy designed to block specific signals in cancer cells, which works differently from traditional chemotherapy.
Will I have to pay for the trial medicine?
No. In UK clinical trials, the investigational medicine and all study-related tests are provided free of charge.
Can I leave the trial if I change my mind?
Yes. You can leave the study at any time and for any reason, without it affecting your relationship with your healthcare team or your future care.
What happens if my cancer gets worse during the study?
If your scans show that the cancer is growing, or if the side effects become too difficult, the study medicine will be stopped and your doctor will discuss other treatment options with you.
How to find out more
TRIANA Clinical Trials
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.